Contract research company Technical Resources International Inc (TRI) reported on Tuesday the receipt of an agreement to conduct the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) study under the Biomedical Advanced Research and Development Authority's (BARDA) Medical Countermeasures Clinical Studies Network and the National Institutes of Health (NIH).
In some COVID-19 patients, the immune system unleashes excessive amounts of proteins that trigger inflammation, called a "cytokine storm", that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. ACTIV-1 IM will evaluate the safety and efficacy of three immune modulator drugs designed to restore balance to an overactive immune system.
NIH's National Center for Advancing Translational Sciences (NCATS) will coordinate and oversee the trial with funding support provided by BARDA, part of the HHS Office of the Assistant Secretary for Preparedness and Response, in support of the Operation Warp Speed goals.
ACTIV-1 IM is expected to enroll 2,100 hospitalized adults with moderate to severe COVID-19 at medical facilities in the US and Latin America. The ACTIV selected three agents from a pool of over 130 immune modulators. The initial agents are infliximab (REMICADE) from Janssen Research & Development LLC, abatacept (ORENCIA) from Bristol Myers Squibb and Cenicriviroc (CVC) from AbbVie.
Under the partnership's trial, all participants will receive remdesivir, the current standard of care treatment of hospitalized patients with COVID-19. They will be randomly assigned to receive a placebo or one of the immune modulators as an add-on treatment. The trial will study the different combination treatment regimens with respect to illness severity, recovery speed, mortality and resource utilisation.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients